SCHEMBL2806964

SCHEMBL2806964

O=C(NCCc1cccs1)NC1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.37
ROCK2 O75116 2/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
AKT1 P31749 1/20 0.36
HTT P42858 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ADAM17 P78536 4/20 0.35
ROCK1 Q13464 2/20 0.35
TAAR1 Q96RJ0 2/20 0.35
ATM Q13315 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CHEK1 O14757 1/20 0.34
DAPK3 O43293 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802722 0.85 EPHX2 (0.49) ROCK2NPC1RAB9ASMN1; SMN2ROCK1
SCHEMBL2834357 0.82 ALDH1A1 (0.40) HTTALDH1A1
SCHEMBL2805664 0.82 EPHX1 (0.51) ROCK2NPC1RAB9ASMN1; SMN2AKT1
SCHEMBL2806628 0.80 ROCK2 (0.47) ROCK2NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL2802252 0.79 EPHX1 (0.47) ROCK2HPGDMAPTROCK1
SCHEMBL2803044 0.78 KMT2A (0.55) SMN1; SMN2HTTMAPTALDH1A1
SCHEMBL2805588 0.77 ROCK1 (0.49) HSD11B1ROCK2NPC1RAB9ASMN1; SMN2
SCHEMBL2807913 0.76 NPC1 (0.42) ROCK2NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL2803078 0.76 FLT3 (0.46) ROCK2KDR
SCHEMBL12338144 0.76 PAK1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 HSD11B1 1915/4885ROCK2 1391/4885NPC1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.